Fingolimod

Red

Brand Name(s):Gilenya

Indication:Multiple sclerosis

Rationale:1,2,8

Considered:May-11

Review Date:Dec-22

Comments:
Drug Safety Updates
Fingolimod (Gilenya): new contraindications in relation to cardiac risk
Fingolimod (Gilenya): updated advice about risk of cancers and serious infections
Dec 2017
…………………………
Drug Safety Update
Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy
April-16
…………………………
Drug Safety Update
Risks of progressive multifocal leukoencephalopathy, basal-cell carcinoma, and opportunistic infections
April-16
…………………………
Drug Safety Update https://assets.digital.cabinet-office.gov.uk/media/56c239a9e5274a036900002b/Gilenya_DHPC_sent_22_Jan_2016.pdf

Drug Safety Update
https://assets.digital.cabinet-office.gov.uk/media/555c338ced915d7ae5000007/Gilenya_DHPC_sent_29_April.pdf
April 2015

NICE CG186 Management of MS in Primary & Secondary Care:
http://www.nice.org.uk/guidance/cg186/resources/guidance-multiple-sclerosis-pdf
Oct 2014

Drug Safety Update: details at http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con344537.pdf
Nov 2013

NICE TA254
Issued: April 2012